Information about NUCYNTA ER. It is titled "NUCYNTA ER demonstrated powerful efficacy in DPN pain". There is a bar graph at the center of the image titled "Mean pain intensity score from baseline over time with NUCYNTA ER or placebo." The x-axis shows time in weeks. The y-axis is labeled "Mean NRS Score (SE)" with a range of values between 2 and 8. The red line representing NUCYNTA starts at a value of between 7 and 8 and decreases rapidly to a value of between 3 and 4 over the first three weeks in a section of the graph labeled "Open-label (OL) period". For weeks 3 through 12 the line graph remains steady at values between 3 and 4. At the three-week mark a yellow line appears to diverge from the red line. It starts at a value between 3 and 4 and quickly rises to values between 4 and 5 where it holds for the remainder of the twelve week period.

Text below the graph indicates that the primary efficacy endpoint was mean change in NRS at Week 12 from the start of the double-blind period (randomization) and that patients randomized to placebo in the double-blind phase and tapered off of the maintenance dose of NUCYNTA ER experienced a worsening of pain by the end of the study. It also reads that the difference in mean pain intensity score between NUCYNTA ER and placebo was statistically significant at the end of the double-blind period.

At the bottom of the page there is a navigation menu and "Opioid Efficacy" appears to be selected. The image also shows a red side bar with the NUCYNTA ER logo and selected important safety information. At the bottom of the sidebar there is a button that says "Click here for more comprehensive safety information".

• Advertisement

• Sales and Marketing